Growth Hormone

Tesamorelin

A GHRH analog approved for HIV-associated lipodystrophy and studied for visceral fat.

What is Tesamorelin?

Tesamorelin is a stabilized GHRH analog that is FDA-approved to reduce excess visceral (abdominal) fat in people with HIV-associated lipodystrophy. It has also been studied for cognitive and metabolic outcomes.

Also known as: TH9507

Read the in-depth Tesamorelin guide

How Tesamorelin is studied

Tesamorelin is a stabilized GHRH analog that boosts the body's growth-hormone axis. Unlike most research peptides, it is FDA-approved for a specific indication — reducing excess visceral (abdominal) fat in people with HIV-associated lipodystrophy — and has also been studied for cognitive and metabolic outcomes.

Commonly researched for

Visceral fat reductionMetabolic healthCognitive studies

Typically stacked with

Ipamorelin

Research status

FDA-approved for a specific indication; studied off-label.

Important considerations

Prescription medication for its approved use. Affects growth hormone axis.

View published research on PubMed

Tesamorelin — frequently asked questions

It is FDA-approved to reduce excess visceral abdominal fat in people with HIV-associated lipodystrophy. Other uses are off-label or investigational.

Its approved evidence is specific to HIV-associated visceral fat. Broader use is not established and it affects the growth-hormone axis.

Yes, for its approved use. It should only be used under medical supervision.

This page is for educational purposes only and is not medical advice, a diagnosis, or a recommendation to use any compound. It contains no dosing or purchase information. Always consult a licensed healthcare professional before considering any peptide.